GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended the approval of Blenrep for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone in patients who have received at least one prior therapy including lenalidomide. An approval decision by the European Commission is expected in the third quarter of 2025. The CHMP opinion follows the approval of Blenrep combinations by the UK Medicines and Healthcare products Regulatory Agency in April and Japan’s Ministry of Health, Labour and Welfare earlier this month.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s Nucala approved by FDA for use in adults with COPD
- GSK reports Nucala approved by FDA for adults with COPD
- Trump Trade: White House announces ‘Golden Dome’ missile-defense shield
- HHS says ‘taking immediate steps to implement’ Trump drug pricing order
- CMS demands on drug pricing ‘extreme,’ ‘highly problematic,’ says Leerink